AstraZeneca unloads respiratory drugs to Covis
Luxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 238 entries already.
Entries by Uta Mommert
Evotec goes for massive IPO on Nasdaq
German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
€40m for Treg starver start-up
Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.
From make-up to jet fuel: Breakthrough for Global Bioenergies
The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.
BICO raises €600m and acquires QInstruments
With €600m from a directed share issue in its coffers, BICO finalises the acquisition of QInstruments, a specialist in advanced sample preparation automation.
European sustainability fund raises €200m
The European Circular Bioeconomy Fund, initiated by the EU, has raised more than €200m that will be used to drive the transformation towards a bio-based economy.
Idorsia: Failure in Phase III
Bad news for Swiss drug discovery company Idorsia: Its Fabry disease hopeful lucerastat failed to reduce neuropathic pain in patients.
Thermo Fisher opens Swiss biologics manufacturing plant
Lengnau will become the newest site in Thermo Fisher Scientific’s biologics manufacturing network. The site is to be completed in 2022 and its staff of 200 will join the company.
UK clears the way for gene-edited crops
Post-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
AstraZeneca invests in saRNA platform
AstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.